Androgen deprivation for minimal metastatic disease: Threshold for achieving undetectable prostate-specific antigen

Urology

Volumn 65, Issue 5, 2005, Pages 947-952

  Beekman, Kathleen ^b   Morris, Michael ^b   Slovin, Susan ^b   Heller, Glenn ^b   Wilton, Andrew ^b   Bianco Jr , Fernando ^b   Scardino, Peter T ^b   Scher, Howard I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CANCER VACCINES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 18844385209     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.12.012     Document Type: Article

References (30)

1. B.F. Hankey, E.J. Feuer, L.X. Clegg Cancer surveillance series: interpreting trends in prostate cancer--part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates J Natl Cancer Inst 91 1999 1017 1024
2. J.W. Moul Prostate specific antigen only progression of prostate cancer J Urol 163 2000 1632 1642
3. D.A. Loblaw, D.S. Mendelsohn, J. Talcott American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progression prostate cancer J Clin Oncol 22 2004 2927 2941
4. M. Bolla, D. Gonzalez, P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
5. M.V. Pilepich, K. Winter, C. Lawton Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate long-term results of phase III RTOG study 85-31 Int J Radiat Oncol Biol Phys 57 2003 S172 S173
6. G.E. Hanks, T.F. Pajak, A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate the Radiation Therapy Oncology Group protocol 92-02 J Clin Oncol 21 2003 3972 3978
7. E.M. Messing, J.B. Zhang, D.J. Rubens Intraoperative optimized inverse planning for prostate brachytherapy early experience Int J Radiat Oncol Biol Phys 44 1999 801 808
8. A.V. D'Amico, J. Manola, M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer a randomized controlled trial JAMA 292 2004 821 827
9. D.P. Petrylak, C.M. Tangen, M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
10. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
11. S.F. Slovin, P. Livingston, S. Zhang Targeted therapy in prostate cancer (PC) vaccination with a glycoprotein, MUC-1-KLH-QS-21 peptide conjugate (abstract) Proc Am Soc Clin Oncol 16 1997 311
12. S. Slovin, G. Ragupathi, R. Israel Ganglioside vaccines in relapsed prostate cancer (PC) experience with GM2-KLH conjugate plus the immunologic adjuvant, QS21--a trial comparing QS21 doses (abstract) Proc Am Soc Clin Oncol 18 1999 316a
13. S.F. Slovin, P.O. Livingston, S. Danishefsky Carbohydrate vaccines as immunotherapy for prostate cancer (PC) Globo-H-KLH conjugate plus QS21 (abstract) Proc Am Soc Clin Oncol 17 1998 433a
14. S.F. Slovin, S. Danishefsky, P.O. Livingston Carbohydrate peptide vaccines in prostate cancer potential for immunotherapy (abstract) Proc Am Assoc Cancer Res 39 1998 370a
15. S.F. Slovin, G. Ragupathi, S. Adluri Carbohydrate vaccines in cancer immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man Proc Natl Acad Sci USA 96 1999 5710 5715
16. S.F. Slovin, G. Ragupathi, J. Olkiewicz Glycosylation of MUC-1-106mer-KLH (GlyMUC-1) conjugate vaccine in biochemically relapsed prostate cancer (PC) patients (Pts) enhances immunogenicity evaluation of GlyMUC-1 for inclusion into a phase III multivalent vaccine trial (abstract) Proc Am Soc Clin Oncol 20 2001 270a
17. S.F. Slovin, G. Ragupathi, K. Olkiewicz Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer clinical trial results with α-N-acetylgalactosamine-O-serine/threonine conjugate vaccine J Clin Oncol 21 2003 4292 4298
18. S.F. Slovin Vaccines as treatment strategies for relapsed prostate cancer approaches for induction of immunity Hematol Oncol Clin North Am 15 2001 477 496
19. A.V. D'Amico, J.W. Moul, P.R. Carroll Cancer specific mortality following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era J Natl Cancer Inst 95 2003 1376 1383
20. L.T. Nordquist, N. Suater, M. Morris Hormonal induction followed by rapid hormonal cycling for prostate cancer (PC) the MEN's cycle (abstract) Proc Am Soc Clin Oncol 23 2004 407
21. J. Morote, E. Trilla, S. Esquena Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer Int J Cancer 108 2004 877 881
22. E.A. Benaim, C.M. Pace, P.M. Lam Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer Urology 59 2002 73 78
23. C. Kwak, S.J. Jeong, M.S. Park Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer J Urol 168 2002 995 1000
24. J.W. Moul, H. Wu, L. Sun Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy J Urol 171 2004 1141 1147
25. C.G. Moertel, T.R. Fleming, J.S. MacDonald Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma N Engl J Med 322 1990 352 358
26. R. Arriagada, B. Bergman, A. Dunant Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
27. P. Eifel, J.A. Axelson, J. Costa National Institutes of Health Consensus Development Conference statement adjuvant therapy for breast cancer, November 1-3, 2000 J Natl Cancer Inst 93 2001 979 989
28. A. Hussain, N. Dawson, P. Amin Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer preliminary results Semin Oncol 28 2001 22 31
29. M.E. Taplin, G.J. Bubley, B. Rajeshkumar Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer Semin Oncol 28 2001 32 39
30. H.I. Scher, M. Eisenberger, A.V. D'Amico Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 22 2004 537 556